Sendai Isawa Family Katsuyama Sake Brewery: SAMURAI SAKE: Reviving a 300-Year-Old Recipe
16.1.2025 06:00:00 CET | Business Wire | Press release
“RYOAN LEGEND 2012 Junmai Daiginjo-DOUBLE UMAMI FINISH - Umami Grand Cru” New Release
Sendai Isawa Family Katsuyama Sake Brewery Co., Ltd.:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250109261916/en/
Presented in a handcrafted Sendai Tansu (Photo: Business Wire)
A Legacy of Supporting Sendai's Samurai Warlord, Date Masamune
Sendai Isawa Family Katsuyama Sake Brewery Co., Ltd., which has a history of over 330 years as the official sake brewer for the Sendai Domain founded by the feudal lord Date Masamune, released RYOAN LEGEND 2012 Junmai Daiginjo-DOUBLE UMAMI FINISH - Umami Grand Cruon December, 2024.
This sake, crafted by unraveling a recipe from 300 years ago, achieves a quality that extracts "twice the umami components of rice" through Katsuyama Brewery's unique centrifugal pressing method. Then, through 12 years of ice aging at minus 5 degrees Celsius, this sake has reached a level of maturity brought about by time.
Shaped by Date Masamune's legacy as a samurai leader and cultural patron, Sendai embodies his vision through international exchange and crafts like Sendai Tansu. Katsuyama Sake Brewery, the Date family's official brewery for over 300 years, honors this heritage while crafting globally renowned sake.
Winner of Prestigious Sake Competitions Worldwide!
Katsuyama Sake Brewery has earned numerous accolades. Junmai Ginjo "Ken" topped the SAKE COMPETITION in 2015 and 2016 and was Champion Sake at the 2019 London IWC. That year, Junmai Daiginjo "Den" won the President Sake title at France's KURA MASTER. Flagship Junmai Daiginjo "Akatsuki" scored 95 points from Robert Parker's Wine Advocate in 2016, ranked first among 800 new sakes, and placed second in the 2024 SAKE COMPETITION Super Premium category.
An Uniquely Exceptional Sake, Reviving a 300-Year-Old Recipe
The theme "Ryoan" honors Heizaemon Isawa, the sixth-generation owner of Katsuyama Sake Brewery, who played a key role in Sendai's growth. His restoration of Zuihō-ji, the Date family's ancestral temple, preserved traditional culture. Inspired by the legacies of Masamune and Heizaemon, RYOAN LEGEND 2012 Junmai Daiginjo embodies Sendai's history, Samurai’s pride, and innovation.
Inspired by Edo-period (1603-1868) sake recipes, this sake combines tradition and innovation. Using historical methods, it amplifies umami, unlocking rice's potential for a rich, smooth finish. Made from 2012 Yamada Nishiki Special A rice, grown near Mount Izumigatake with silica-rich water, it reflects Katsuyama’s unique terroir. With centrifugal extraction and 12 years of cold aging, it achieves a perfect balance of depth, umami, and crispness.
Presented in a handcrafted Sendai Tansu, this limited release of 50 sets offers an unparalleled experience of premium rice’s sake.
RYOAN LEGEND 2012 Junmai Daiginjo-DOUBLE UMAMI FINISH - Umami Grand Cru |
Ingredients: Rice (domestic), Rice Koji (domestic rice) |
Polishing Ratio: 35% |
Rice Variety: 100% Yamada Nishiki |
Alcohol Content: 16% |
Volume: 720ml |
Storage: Refrigerated (room temperature during transport is acceptable) |
Brewmaster: Mitsuaki Goto |
Recommended Serving Temperature: 8–14°C |
Price: ¥1,000,000 (excluding tax) |
Sales: Limited to 50 bottles |
View source version on businesswire.com: https://www.businesswire.com/news/home/20250109261916/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom